Companies › Celltrion
5 active drug programs in 5 registered trials: 4 Phase 3, 1 Phase 1; Oncology, Neurology, Other, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CT-P51 PD-1 inhibitor | PDCD1 | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Feb 2027 |
| Ocrelizumab (P53) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Relapsing-remitting Multiple Sclerosis | Feb 2027 |
| CT-P44 anti-CD38 monoclonal antibody | CD38 | Phase 3 | Refractory or Relapsed Multiple Myeloma | Mar 2027 |
| Secukinumab (P55) Interleukin 17A inhibitor | IL17A | Phase 3 | Plaque Psoriasis | – |
| CT-P52 IL-17A inhibitor biosimilar | IL17A | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06630559 | Secukinumab (P55) | Phase 3 | Plaque Psoriasis | Immunology | Feb 2026 |
| NCT07200986 | CT-P52 | Phase 1 | Healthy Participants | Other | Mar 2026 |
| NCT05906992 | Ocrelizumab (P53) | Phase 3 | Relapsing-remitting Multiple Sclerosis | Neurology | Feb 2027 |
| NCT06939595 | CT-P51 | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT06952478 | CT-P44 | Phase 3 | Refractory or Relapsed Multiple Myeloma | Oncology | Mar 2027 |
R-Pharm Biocad RemeGen Sinocelltech Taizhou Mabtech Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.